本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Neoleukin Therapeutics, Inc.

3.49
0.0000
成交量:- -
成交額:39.34萬
市值:3,279.87萬
市盈率:-1.14
高:3.49
開:3.49
低:3.49
收:3.49
52周最高:4.70
52周最低:1.90
股本:939.79萬
流通股本:544.90萬
量比:- -
換手率:- -
股息:- -
股息率:- -
每股收益(TTM):-3.0649
每股收益(LYR):-5.2115
淨資產收益率:-37.88%
總資產收益率:-18.70%
市淨率:0.44
市盈率(LYR):-0.67

資料載入中...

2023/08/10

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/07/28

超過5%披露

Form SC 13D - General statement of acquisition of beneficial ownership
2023/07/19

超過5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2023/07/18

企業合併公告

Form 425 - Prospectuses and communications, business combinations
2023/07/18

重要事件披露

Form 8-K - Current report
2023/07/18

企業合併公告

Form 425 - Prospectuses and communications, business combinations
2023/06/13

重要事件披露

Form 8-K - Current report
2023/05/08

季度報告

10-Q - Quarterly report [Sections 13 or 15(d)]
2023/04/03

重要事件披露

8-K - Current report
2023/03/21

員工持股計劃

S-8 - Securities to be offered to employees in employee benefit plans
2023/03/20

年度報告

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2023/03/10

重要事件披露

8-K - Current report
2023/03/08

重要事件披露

8-K - Current report
2023/02/14

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/02/03

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2023/01/23

重要事件披露

8-K/A [Amend] - Current report
2023/01/19

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/12/30

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2022/11/30

重要事件披露

8-K - Current report
2022/11/14

重要事件披露

8-K - Current report